Clinical Trials Directory

Trials / Completed

CompletedNCT03575949

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

Dual-Time Point (DTP) FDG PET CT for the Post-Treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
14 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This trial studies how well standard and delayed fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) given after standard radiation and chemotherapy works in assessing patients with head and neck squamous cell cancer that has spread to other places in the body. Diagnostic procedures, such as PET/CT, use radioactive material, such as fludeoxyglucose F-18, to find and diagnose head and neck tumors and may help to find out how far the disease has spread.

Detailed description

PRIMARY OBJECTIVE: I. To assess the optimal imaging time using FDG positron emission tomography (PET) with comparison between a standard of care 1-hour scan (early) and the research scan of 3-hours scan (delayed) post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma (measured as lesion/background \[L/B\] ratio) in patients with head and neck primary squamous cell carcinoma following chemoradiation treatment. OUTLINE: Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard chemoradiation (CRT) completion. After completion of study, patients are followed up at 30 days and then periodically for up to 6 months.

Conditions

Interventions

TypeNameDescription
PROCEDUREComputed TomographyUndergo FDG PET/CT
OTHERFludeoxyglucose F-18Given IV
PROCEDUREPositron Emission TomographyUndergo FDG PET/CT

Timeline

Start date
2018-06-15
Primary completion
2024-05-10
Completion
2024-05-10
First posted
2018-07-03
Last updated
2024-05-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03575949. Inclusion in this directory is not an endorsement.